SMMT

SMMT

USD

Summit Therapeutics Inc. Common Stock

$17.490-0.290 (-1.631%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$17.780

High

$18.120

Low

$17.370

Volume

2.88M

Company Fundamentals

Market Cap

13.0B

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

4.10M

Exchange

NGM

Currency

USD

52-Week Range

Low $15.55Current $17.490High $36.91

Related News

BusinessWire

Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the

View more
Summit Therapeutics to Present at Upcoming Investor Conferences
BusinessWire

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the

View more
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Analyst Upgrades

Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target

Guggenheim analyst Brad Canino reiterates Summit Therapeutics with a Buy and maintains $40 price target.

View more
Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target
BusinessWire

Summit Therapeutics Raises $500 Million in Private Placement

Fundraise Led by Leading Biopharma Institutional Investors & Insiders $500 Million in Gross & Net Proceeds Raised at Yesterday's Closing Price of $18.74 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit,"

View more
Summit Therapeutics Raises $500 Million in Private Placement
Analyst Upgrades

Barclays Maintains Underweight on Summit Therapeutics, Raises Price Target to $16

Barclays analyst Etzer Darout maintains Summit Therapeutics with a Underweight and raises the price target from $13 to $16.

View more
Barclays Maintains Underweight on Summit Therapeutics, Raises Price Target to $16
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $40

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics with a Buy and lowers the price target from $50 to $40.

BusinessWire

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Conference Call to be Held at 8:00am ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the